Rescuing clinical trials in the united states and beyond:A call for action

American Heart Journal

Volumn 165, Issue 6, 2013, Pages 837-847

  Eapen, Zubin J ^a   Vavalle, John P ^a   Granger, Christopher B ^a   Harrington, Robert A ^b   Peterson, Eric D ^a   Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CONFERENCE PAPER; CONSENSUS; FOLLOW UP; GOVERNMENT; HUMAN; INDUSTRY; PRIORITY JOURNAL; PROBLEM SOLVING; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

EID: 84880081205     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.02.003     Document Type: Conference Paper

References (62)

1. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009;301:831-41.
2. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360:816-23.
3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 1045-57.
4. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544-54.
5. Moses III H, Dorsey ER, Matheson DH, et al. Financial anatomy of biomedical research. JAMA 2005;294:1333-42.
6. Burrill SG. Biotech Life Sciences 2005: A move toward predictability. San Francisco, CA: Burrill & Co.; 2005.
7. DiMasi JA, Hansen RW, Grabowski HG, et al. Cost of innovation in the pharmaceutical industry. J Health Econ 1991;10:107-42.
8. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003;22: 151-85.
9. Garnier JP. Rebuilding the R&D engine in big pharma. Harv Bus Rev 2008;86:68-70, 72-6, 128.
10. Kaitin KI, editor. Global site landscape remains highly fragmented with variable performance. Tufts CSDD Impact Report. 2013;15:2.
11. Califf RM, Harrington RA. American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy? J Am Coll Cardiol 2011;58:677-80.
12. Levinson D. Challenges to FDA's ability to monitor and inspect foreign clinical trials. The Office of Inspector General U.S. Department of Health & Human Services Web site. https://oig.hhs.gov/oei/reports/oei-01-08-00510.pdf Updated June 2010. Accessed January 31, 2013.
13. Kim ES, Carrigan TP, Menon V. International participation in cardiovascular randomized controlled trials sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2011; 58:671-6.
14. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981-92.
15. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365:32-43.
16. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
17. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366: 20-33.
18. O'Connor CM, Fiuzat M, Swedberg K, et al. Influence of global region on outcomes in heart failure beta-blocker trials. J Am Coll Cardiol 2011;58:915-22.
19. Fox KA, Goodman S, Bigonzi F, et al. Inter-regional differences and outcome in unstable angina; analysis of the international ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Qwave Coronary Events. Eur Heart J 2000;21:1433-9.
20. Gelijns AC, Gabriel SE. Looking beyond translation-integrating clinical research with medical practice. N Engl J Med 2012;366: 1659-61.
21. Menikoff J. The paradoxical problem with multiple-IRB review. N Engl J Med 2010;363:1591-3.
22. Infectious Diseases Society of America. Grinding to a halt: The effects of the increasing regulatory burden on research and quality improvement efforts. Clin Infect Dis 2009;49:328-35.
23. Getz KA, Wenger J, Campo RA, et al. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther 2008;15:450-7.
24. Charlton Research Company for Research!America. America speaks: Poll data summary, volume 10. Research!America Web site. http://www.researchamerica.org/ uploads/AmericaSpeaksV10.pdf Accessed February 5, 2013.
25. Schaefer GO, Emanuel EJ, Wertheimer A. The obligation to participate in biomedical research. JAMA 2009;302:67-72.
26. Brownlee S, Winters D. Bad science and breast cancer. Discover Magazine Web site. http://discovermagazine.com/2002/aug/featbad Updated August 1, 2002. Accessed January 31, 2013.
27. Califf RM. Clinical research sites-the underappreciated component of the clinical research system. JAMA 2009;302:2025-7.
28. Koski G, Widler B, Olmsted A. A global clinical research network: Moving beyond harmonisation. Scrip Regulatory Affairs Web site. http://www.rajpharma. com/productsector/medicaldevices/A-global-clinical-research-network-moving- beyondharmonisation-318216 Updated July 8, 2011. Accessed January 31, 2013.
29. Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation: Executive Office of the President, President's Council of Advisors on Science and Technology; September 2012. The White House Web site. http://www. whitehouse.gov/sites/default/files/microsites/ostp/pcast- fda-final. pdf Updated September 2012. Accessed January 31, 2013.
30. Health Care Innovation Challenge: U.S. Department of Health & Human Services, Centers for Medicare & Medicaid Services, Center for Medicare & Medicaid Innovation: Cooperative Agreement Initial Announcement. Grants.gov Web site. http://apply07.grants.gov/apply/opportunities/instructions/ oppCMS-1C1-12-001-cfda93. 610-cidCMS-1C1-12-001-013123-instructions.pdf Updated November 14, 2011. Accessed January 31, 2013.
31. Moss AJ, Francis CW, Ryan D. Collaborative clinical trials. N Engl J Med 2011;364:789-91.
32. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
33. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
34. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
35. English R, Lebovitz Y, Griffin RB. Transforming clinical research in the US: Challenges and opportunities. Washington, DC: The National Academies Press; 2010.
36. Guidance for industry: Using a centralized IRB review process in multicenter clinical trials. The U.S. Food and Drug Administration Web site. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127013.pdf Updated March 2006. Accessed January 31, 2013.
37. Request for information and comments on IRB accountability. U.S. Department of Health & Human Services Web site. http://www.hhs. gov/ohrp/newsroom/rfc/com030509.html Updated March 5, 2009. Accessed February 27, 2013.
38. Abbott D, Califf R, Morrison BW, et al. Cycle time metrics for multisite clinical trials in the US. Ther Innov Reg Sci 2013;00:1-9.
39. The European Parliament and the Council of the European Union. On the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. European Organisation for the Research and Treatment of Cancer Web site. http://www.eortc.be/Services/Doc/clinical-EU-directive-04-April-01.pdf Updated April 1, 2001. Accessed February 4, 2013.
40. CTSA Consortium Coordinating Center. IRBshare Web site. https://www.irbshare.org/about.php Accessed January 17, 2013.
41. Flynn KE, Hahn CL, Kramer JM, et al. Using central IRBs for multicenter clinical trials in the US. In press.
42. Childhood Arthritis and Rheumatology Research Alliance Web site. https://www.carragroup.org Updated January 2013. Accessed January 31, 2013.
43. Pediatrics Trials Network Web site. https://pediatrictrials.org Updated January 2012. Accessed January 31, 2013.
44. Improving unexpected SAE reporting to IND investigators. Clinical Trials Transformation Initiative Web site. https://www.ctticlinicaltrials.org/project- topics/adverse-events/improvingunexpected-sae-reporting-to-ind-investigators/ improvingunexpected-sae-reporting-to-ind-investigators/?searchterm=sae Accessed January 17, 2013.
45. Centers for Medicare & Medicaid Services. Pilot program for parallel review of medical products. Federal Register Web site. Updated October 11, 2011. Accessed January 31, 2013.
46. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol 2009;27:26-34.
47. Eisenstein EL, Lemons II PW, Tardiff BE, et al. Reducing the costs of Phase III cardiovascular clinical trials. Am Heart J 2005;149: 482-8.
48. Frobert O, Lagerqvist B, Gudnason T, et al. Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale. Am Heart J 2010; 160:1042-8.
49. McCourt B, Barham B, Melton L, et al. Transforming Research through a National Cardiovascular Research Infrastructure. Poster presented at: 2010 AMIA Clinical Research Informatics Summit: March 12-13, 2010; San Francisco, CA; 2010.
50. Weisfeld N, English RA, Claiborne AB, et al. Envisioning a transformed clinical trials enterprise in the US: Establishing an agenda for 2020: Workshop summary. Washington, DC: The National Academies Press; 2012.
51. Olsen L, Aisner D, McGinnis JM. The learning healthcare system: Workshop summary. Washington, DC: The National Academies Press; 2007.
52. Behrman RE, Benner JS, Brown JS, et al. Developing the Sentinel System-A national resource for evidence development. N Engl J Med 2011;364:498-9.
53. Mini-sentinel distributed database "at a glance." Mini-Sentinel Web site. http://mini-sentinel.org/about-us/MSDD-At-a-Glance.aspx Updated December 31, 2012. Accessed January 31, 2013.
54. The Collaboratory. Health Care Systems Research Collaboratory Web site. https://www.theresearchcollaboratory.org/Updated January 2013. Accessed January 31, 2013.
55. Norman GR, Shannon SI, Marrin ML. The need for needs assessment in continuing medical education. BMJ 2004;328:999-1001.
56. ABIM Foundation, American Board of Internal medicine, ACP-ASIM Foundation, et al. Medical professionalism in the new millennium: A physician charter. Ann Intern Med 2002;136:243-6.
57. Swick HM. Toward a normative definition of medical professionalism. Acad Med 2000;75:612-6.
58. Eisenberg P, Kaufmann P, Sigal E, et al. Developing a clinical trials infrastructure in the US. Institute of Medicine Web site. http://www. iom.edu/~/media/Files/Perspectives-Files/2012/Discussion-Papers/ HSP-Drugs-Developing-a-Clinical-Trial-%20Infrastructure. pdf Updated April 13, 2012. Accessed January 31, 2013.
59. Olsen LA, Aisner D, McGinnis JM, editors. The learning healthcare system: Workshop summary. Washington, DC: National Academies Press (US); 2007.
60. Kass NE, Faden RR, Goodman SN, et al. The research-treatment distinction: A problematic approach for determining which activities should have ethical oversight. Hastings Cent Rep 2013;43:S4-S15.
61. Faden RR, Kass NE, Goodman SN, et al. An ethics framework for a learning health care system: A departure from traditional research ethics and clinical ethics. Hastings Cent Rep 2013;43:S16-27.
62. Armitage J, Souhami R, Friedman L, et al. The impact of privacy and confidentiality laws on the conduct of clinical trials. Clin Trials 2008; 5:70-4.